Citigroup Inc Harrow Health, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Citigroup Inc holds 25,502 shares of HROW stock, worth $894,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,502

Previous 9,734 161.99%

Holding current value

$894,610

Previous $203,000 464.53%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$20.85 - $46.47 $328,762 - $732,738	15,768 Added 161.99%	25,502 $1.15 Million
Q2 2024 Aug 12, 2024	BUY	$10.0 - $21.64 $45,960 - $99,457	4,596 Added 89.45%	9,734 $203,000
Q1 2024 May 10, 2024	BUY	$9.3 - $13.23 $2,083 - $2,963	224 Added 4.56%	5,138 $67,000
Q4 2023 Feb 09, 2024	SELL	$8.1 - $16.36 $10,489 - $21,186	-1,295 Reduced 20.86%	4,914 $55,000
Q3 2023 Nov 09, 2023	SELL	$14.03 - $22.08 $83,506 - $131,420	-5,952 Reduced 48.94%	6,209 $89,000
Q2 2023 Aug 10, 2023	SELL	$17.37 - $28.08 $852,102 - $1.38 Million	-49,056 Reduced 80.13%	12,161 $231,000
Q1 2023 May 11, 2023	SELL	$13.84 - $21.46 $3,473 - $5,386	-251 Reduced 0.41%	61,217 $1.3 Million
Q4 2022 Feb 09, 2023	BUY	$10.28 - $14.78 $514,750 - $740,078	50,073 Added 439.43%	61,468 $907,000
Q3 2022 Nov 10, 2022	BUY	$6.57 - $24.88 $72,270 - $273,680	11,000 Added 2784.81%	11,395 $138,000
Q2 2022 Aug 10, 2022	SELL	$5.75 - $7.74 $971 - $1,308	-169 Reduced 29.96%	395 $3,000
Q1 2022 May 12, 2022	SELL	$6.77 - $8.66 $1,563 - $2,000	-231 Reduced 29.06%	564 $4,000
Q4 2021 Feb 10, 2022	BUY	$8.5 - $12.0 $6,757 - $9,540	795 New	795 $7,000

Others Institutions Holding HROW

# of Institutions

177

Shares Held

21.4M

Call Options Held

845K

Put Options Held

717K

View Full List

About HARROW HEALTH, INC.

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $950M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

More about HROW

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account